Titan Medical Inc. Appoints Dr. Li-Ming Su to Its Medical Advisory Board
TORONTO, ONTARIO -- (MARKET WIRE) -- 06/07/11 -- Titan Medical Inc. ("the Company") (TSX VENTURE: TMD) announced today that it has appointed Dr. Li-Ming Su, M.D., to the Company's Medical Advisory Board.
"We are very pleased to welcome Dr. Li-Ming Su to our world-class Medical Advisory Board," said Dr. Reiza Rayman, President of Titan Medical Inc. "The addition of Dr. Li-Ming Su strengthens our expertise in robotic surgery for urology where he will play an integral part in our development and clinical path towards the commercialization of Amadeus™."
"I am pleased to join Titan's exceptional Medical Advisory Board," said Dr. Li-Ming Su. "For over 10 years I have had experience in both testing and working with transformational robotic surgery technologies. To play an essential role in advancing robotic surgery for the next generation with the development of Amadeus™ is both exciting and humbling. I look forward to collaborating with the group at Titan Medical and to the prospect of helping to further the development of Amadeus™."
Dr. Li-Ming Su is the David A. Cofrin Professor of Urology, Associate Chairman for Clinical Affairs and the Director of Robotic and Minimally Invasive Urologic Surgery in the Department of Urology at the University of Florida College of Medicine in Gainesville, Florida. Previously, he was an Associate Professor of Urology at The Johns Hopkins University School of Medicine and Director of Laparoscopic and Robotic Urologic Surgery in Hopkins' Brady Urological Institute. He joined the urology staff at Johns Hopkins after completing his urology residency at New York Presbyterian Hospital-Cornell University Medical College and fellowship training in endourology (specializing in laparoscopy, robotics and stone disease) at Johns Hopkins. His main clinical interests include minimally invasive techniques for the treatment of kidney and prostate cancer. His areas of surgical specialty include robotic partial nephrectomy, nerve-sparing radical prostatectomy, pyeloplasty, nephroureterectomy and adrenalectomy. He has earned a number of honors and awards in urology and robotic surgery. Additionally, his publishing accomplishments include 74 refereed publications, 8 non-refereed publications, two authored books on robotic urologic surgery and prostate cancer, 21 book chapters, and 122 abstracts.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus™, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The current global robotic surgical market size is approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 31, 2011 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer (416) 548-7522 (ext. 151) cleon@titanmedicalinc.com www.titanmedicalinc.com ICR, LLC Sherry Bertner Managing Director (646) 277-1247 Sherry.Bertner@icrinc.com
Source: Titan Medical Inc.
Released June 7, 2011